Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects

This is a fairly clean efficacy setup: insulin-naive type 2 diabetes patients on metformin alone or with an SGLT2 agent are a standard population, and change in HbA1c at 20 weeks is an objective, validated endpoint with limited measurement noise. Those features reduce random failure risk. The main offset is the comparator: insulin glargine is an effective active control, so this is not an easy bar if SHR-3167 must show clear glycemic competitiveness. The trial fields also do not state whether the analysis is superiority or noninferiority, provide no margin, no sample-size context, and no prior SHR-3167 efficacy signal; that missing context meaningfully lowers conviction in a Phase 2 study where dose selection and powering often drive outcomes. Operationally, Active Not Recruiting with primary completion just passed suggests enrollment/execution risk is lower than for an early or delayed study, but analysis and disclosure still carry some uncertainty. Overall, strong endpoint quality is outweighed by the active-control hurdle and limited prior signal.

SHR-3167 is a once-weekly basal insulin from Hengrui, following the validated class pathway of insulin icodec (Awiqli). Phase 1 data showed favorable PK/PD: similar glucose-lowering (AUCGIR) at 0.6 mg/kg vs daily glargine, linear dose-response, half-life of 10.8-12.1 days supporting weekly dosing, good safety with only one asymptomatic hypoglycemia event. The Phase 2 trial design (treat-to-target, open-label, HbA1c primary at 20 weeks, ~273 patients, insulin-naïve T2D on metformin±SGLT2i vs glargine) closely mirrors icodec's ONWARDS program which consistently demonstrated noninferiority and even superiority. The class precedent is very strong: icodec achieved noninferiority in all 5 ONWARDS trials. However, SHR-3167's molecular details differ from icodec, and Phase 2 is dose-finding with potential for suboptimal dose selection. The open-label design reduces blinding bias risk but may not resolve all confounders. Hengrui is an experienced sponsor. Primary completion is already past (-3 days), but no results disclosed yet. Moderate-high probability of positive results, tempered by Phase 2 uncertainty and Chinese-only sites.

This is a Phase 2 trial comparing SHR-3167 (a novel GLP-1 or similar mechanism likely) against insulin glargine in insulin-naïve T2D patients. Active-comparator trials are harder to demonstrate 'positive' results than placebo-controlled studies, as the drug must show non-inferiority or superiority to an established standard. HbA1c is a validated endpoint, and the 20-week duration is appropriate. The sponsor is a major Chinese pharma company with decent track record. However, Phase 2 data is limited, and without prior Phase 1 readout or scientific publications, intrinsic probability is uncertain. Historical Phase 2 success rates in diabetes are moderate, but active-comparator designs reduce win probability. Given the lack of disclosed prior data, the base case is near 50% with low confidence.

This is a Phase 2 trial comparing SHR-3167 to insulin glargine in insulin-naïve T2D patients. The primary endpoint is change in HbA1c at 20 weeks, a standard, objective, and well-accepted efficacy measure in diabetes. The population is well-defined, and the comparator is a standard-of-care basal insulin. The primary completion date has just passed (-3 days), suggesting data is likely being analyzed, reducing operational timeline risk. However, the intrinsic probability is only modestly above 50% due to typical Phase 2 attrition, unknown efficacy delta versus an active control, and the risk of safety signals emerging as a primary reason for failure. The sponsor, HengRui, has diabetes development experience.

Phase 2 head-to-head trial tests SHR-3167 (likely novel GIP/GLP-1 dual agonist from HengRui's incretin pipeline) vs insulin glargine for HbA1c reduction at 20 weeks in insulin-naïve T2D patients on metformin ± SGLT2i. Primary endpoint is robust, continuous, clinically meaningful surrogate with low noise. Patient population is standard, early-line add-on setting where basal insulin is common but incretins excel (e.g., tirzepatide outperformed glargine by 0.4-0.5% HbA1c in SURPASS-3, similar design). 20-week duration sufficient for steady-state HbA1c. Sponsor Jiangsu HengRui is execution-strong in diabetes (multiple GLP-1 assets advancing). Status active not recruiting with primary completion imminent (-3 days) indicates smooth operations, no major delays. No prior dose-finding or efficacy data provided raises uncertainty on dosing potency, placebo-adjusted effect size, or powering (assumed superiority). Chinese sponsor poses minor disclosure risk (timely topline expected). Balanced risks favor positive outcome: class precedent + comparator mismatch (fixed-dose incretin vs titratable insulin) yield 62% YES probability.

The trial compares SHR-3167 (insulin glargine) against insulin glargine in a non-inferiority design. Given the established safety profile and efficacy of insulin glargine, SHR-3167 needs only to demonstrate non-inferiority, a relatively low bar for a Phase 2 trial. The primary endpoint of HbA1c reduction is a well-established, objective measure, reducing execution risk. The sponsor, Jiangsu Hengrui Medicine, has a strong track record in oncology and is expanding into metabolic diseases. The primary completion date has passed (March 2026), and with the status 'Active, not recruiting', data analysis is likely underway. The probability of a positive outcome is high, given the established mechanism of insulin glargine and the standard trial design.

Phase 2 trial comparing SHR-3167 (novel agent) to insulin glargine in metformin±SGLT2-treated T2D patients. Primary endpoint is standard HbA1c reduction at 20 weeks—well-powered, clinically relevant. Insulin glargine is active comparator with established efficacy, making non-inferiority/superiority achievable. Chinese sponsor with track record in diabetes (HENGRUI). Trial completed primary completion 3 days ago—results imminent. No red flags in design: insulin-naïve population, adequate duration. Disclosure risk elevated given completion proximity. Prior Phase 1 data likely supportive to advance to Phase 2. Baseline probability of positive outcome in well-run Phase 2 diabetes trials with active comparator typically 55-70%.

SHR-3167 is a novel once-weekly basal insulin developed by Hengrui. This Phase 2 trial compares it to daily insulin glargine in insulin-naive Type 2 diabetes patients over 20 weeks, with the primary endpoint being the change in HbA1c from baseline. In such treat-to-target insulin trials, doses are actively titrated to achieve target fasting plasma glucose levels, which effectively ensures robust and comparable HbA1c reductions across both the experimental and active comparator arms. Prior once-weekly insulins (such as Novo Nordisk's icodec and Eli Lilly's efsitora alfa) have consistently demonstrated non-inferiority to daily basal insulins in similar populations. Furthermore, Phase 1 data for SHR-3167 previously demonstrated dose-dependent HbA1c reductions, predictable pharmacokinetics, and an acceptable tolerability profile, significantly de-risking the core mechanism of action. Hengrui is an experienced sponsor with a strong track record in late-stage clinical execution, minimizing operational risk. Given the established efficacy of the once-weekly basal insulin class and the treat-to-target design, the trial has a very high probability of meeting its primary endpoint.

The trial is in Phase 2, evaluating the efficacy and safety of SHR-3167 compared to insulin glargine in type 2 diabetes patients. The primary endpoint is change from baseline to week 20 in HbA1c. Given that the trial is still active but not recruiting, and considering the complexity of diabetes treatment trials, there's a moderate chance of positive results. However, the current status and phase suggest uncertainty, leading to a slightly below 50% probability of a positive outcome.